Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Maria L. Villalobos"'
Autor:
Maria L. Villalobos, Guillermo Velasco, Alejandro Riquelme, Iciar Garcia Carbonero, Isabel Gallegos, Enrique Grande, Alvaro Pinto, Javier Puente, Pablo Gajate, Constanza Maximiano Alonso, Laura Rodriguez, Carmen Perezagua, Carlos Aguado De La Rosa, Almudena Martin, Jf. Rodriguez-Moreno, María J. Garrido, Teresa Alonso, María Sereno, Javier Cassinello, David Marrupe
Publikováno v:
Journal of Clinical Oncology. 35:e16504-e16504
e16504 Background: In the CHAARTED and STAMPEDE clinical trials, Docetaxel combined with androgen-deprivation therapy (ADT) increased overall survival in mHSPC patients. Despite the increasing use of this strategy in clinical practice, there is a lac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::360bc6a55a51908e65d1d171f395cb49
https://doi.org/10.1200/jco.2017.35.15_suppl.e16504
https://doi.org/10.1200/jco.2017.35.15_suppl.e16504
Autor:
Alejo Rodriguez Vida, Jose David Cumplido Buron, Begoña Perez-Valderrama, Beatriz Pelaez Lorenzo, Begoña Campos Balea, Pablo Borrega, Iria González-Maeso, Iciar Garcia Carbonero, Emilio Esteban, Daniel Castellano, Rosa Garcia Marrero, Jose Maria Garcia-Bueno, Maria L. Villalobos, Jose Garcia Sanchez, Gustavo Rubio, Ruth Viciana, Nuria Lainez, Almudena Martin, Joaquim Bellmunt, Javier Munarriz
Publikováno v:
Journal of Clinical Oncology. 35:e602-e602
e602 Background: The clinical experience with CBZ in mCRPC patients (pts) has enriched notably since its approval for clinical use, but there is still a lack of well-defined prognostic/predictive factors to better characterize the profile of pts that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e37420e76066302e3c5bb4f809d7a9e
https://doi.org/10.1200/jco.2017.35.6_suppl.e602
https://doi.org/10.1200/jco.2017.35.6_suppl.e602
Autor:
Rocío García Domínguez, A. Sánchez, Blanca Cantos, David Marrupe, Alvaro Pinto, Marta Lopez Brea, Marta Juan, Maria L. Villalobos, Guillermo Velasco, Sergio Vazquez-Estevez, Javier L. Puertas, Teresa de Portugal, María Sereno, Rocio Vilchez, María J. Garrido, Manuel Constenla, Gustavo Rubio, Jose-Luis Gonzalez-Larriba, Javier Puente, Jose Angel Arranz Arija
Publikováno v:
ResearcherID
e15609 Background: In clinical trials pazopanib (P) was superior to placebo, noninferior to sunitinib, and very well tolerated as 1st-line for mRC, but there is limited information in daily clinical practice. Methods: We retrospectively reviewed 159
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eb959b2e131469f245350585f81b4c4
https://doi.org/10.1200/jco.2013.31.15_suppl.e15609
https://doi.org/10.1200/jco.2013.31.15_suppl.e15609